Fengchun Zhang
Peking Union Medical College Hospital
2
2
2
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (2)
Research Network
Collaboration Network
Research Areas & Affiliations
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Xianyun Wang, Doctor
The First Hospital of Hebei Medical University
Shared therapeutic areas:
Qiubai Li, Professor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Shared therapeutic areas:
Veronique Leguern, MD
Service de Médecine Interne, Hôpital Cochin, 27, rue du Faubourg Saint-Jacques, 75679 PARIS Cedex 14.
Shared therapeutic areas:
Sabine Hazan, MD
ProgenaBiome
Shared therapeutic areas:
Luc Mouthon, MD
Service de Médecine Interne, Hôpital Cochin, 27, rue du Faubourg Saint-Jacques, 75679 PARIS Cedex 14. Email: luc.mouthon@cch.aphp.fr
Shared therapeutic areas:
Colleen Annesley, MD
Seattle Children's Hospital
Shared therapeutic areas:
Michelle Petri, MD
Dept of Rheumatology, 1830 Building, Suite 7500. Email: mpetri@jhmi.edu
Shared therapeutic areas:
Loïc Guillevin, MD
Service de Médecine Interne, Hôpital Cochin, 27, rue du Faubourg Saint-Jacques, 75679 PARIS Cedex 14. Email: loic.guillevin@wanadoo.fr
Shared therapeutic areas:
xiaofeng zeng
Peking Union Medical College Hospital
Shared therapeutic areas:
Ronald F. van Vollenhoven, MD
Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska University Hospital, D10:0, Department of Rheumatology, 17176 Stockholm, Sweden. Email: Ronald.van.Vollenhoven@ki.se
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (2)
Showing 2 of 2 trials
A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.
Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)
All 2 trials loaded